[Cytokines in bone diseases. BMP signaling and fibrodysplasia ossificans progressiva].
Fibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant disorder characterized by progressive heterotopic bone formation in skeletal muscle tissue. In 2007, FOP was authorized as one of the Intractable Disorders by the Ministry of Health, Labour and Welfare of Japan. The Research Committee on FOP is working on the molecular mechanisms underlying heterotopic bone formation and the development of new treatments for FOP.
Katagiri
Takenobu
T
Division of Pathophysiology, Research Center for Genomic Medicine, Saitama Medical University.
Kamizono
Jyunji
J
Nakashima
Yasuharu
Y
Kitoh
Hiroshi
H
Susami
Takafumi
T
Haga
Nobuhiko
N
D030201:Activin Receptors, Type I / Q000235:genetics / Q000378:metabolism; D019485:Bone Morphogenetic Proteins / Q000502:physiology*; D055808:Drug Discovery; D005799:Genes, Dominant; D006801:Humans; D058990:Molecular Targeted Therapy; D009154:Mutation; D009221:Myositis Ossificans / Q000188:drug therapy / Q000235:genetics; D011720:Pyrazoles / Q000494:pharmacology / Q000627:therapeutic use; D011743:Pyrimidines / Q000494:pharmacology / Q000627:therapeutic use; D015398:Signal Transduction / Q000502:physiology*; D016212:Transforming Growth Factor beta / Q000502:physiology*
D019485:Bone Morphogenetic Proteins; C554430:LDN 193189; D011720:Pyrazoles; D011743:Pyrimidines; D016212:Transforming Growth Factor beta; C425423:ACVR1 protein, human; D030201:Activin Receptors, Type I